Compare Adaptive Biotechnologies Corp (ADPT) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Nuscale Power Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Nuscale Power Corporation trades at $8.78 (market cap $3.10B). The key difference: Adaptive Biotechnologies Corp and Nuscale Power Corporation are close in size by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| ADPT | SMR | |
|---|---|---|
Market Cap | $3.33B | $3.10B |
Sector | Health | Utilities |
52-Week High | $22.37 | $53.43 |
52-Week Low | $10.24 | $8.96 |
Enterprise Value | $3.19B | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NuScale Power (SMR) trades at $9.61, down 1.54% on the day, reflecting ongoing bearish technical momentum. The company shows severe financial strain with a net income margin of -2,066.55% and negative cash flow from operations of $459.61 million in 2025. Despite this, analyst consensus remains optimistic with a $13.00 price target, and recent news highlights potential long-term growth from SMR technology commercialization and partnerships like ENTRA1.
The outlook is highly speculative; significant upside exists if NuScale successfully commercializes its reactors by the 2030s, but near-term risks include persistent losses, high cash burn, and execution hurdles. Investors face substantial volatility with the stock near its 52-week low, requiring high risk tolerance for potential multi-bagger returns amid operational and competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
